Prescient Therapeutics Investor Briefing Replay

Prescient Therapeutics Webcast Replay

  • The exclusive and global licence agreement with The University of Pennsylvania (UPenn).
  • An introduction to UPenn’s universal CAR-T Platform (OmniCAR) under licence to PTX.
  • Updated the market regarding PTX’s licence, develop and collaborate business model towards personalised cancer therapies and improved patient outcomes.

Recorded on 26th May 2020 at 12pm (AEST).

Learn more about Prescient Therapeutics

Register for PTX Updates and Announcements


Steven Yatomi Clarke

CEO and Managing Director

Register for updates

[wpforms id="22015"]